Company pipelines
Drug pipeline tracking for the companies behind the experimental drugs we profile. Each page combines live registry statistics from ClinicalTrials.gov with tracked drug profiles and sourced milestones.
| Company | Listing | Active trials (lead sponsor) | Active Phase 3 | Tracked drugs |
|---|---|---|---|---|
| Amgen Thousand Oaks, California, United States | Nasdaq: AMGN | 104 | 50 | Olpasiran |
| Eli Lilly and Company Indianapolis, Indiana, United States | NYSE: LLY | 241 | 94 | Retatrutide, Orforglipron, Lepodisiran, Muvalaplin |
| Merck & Co. Rahway, New Jersey, United States | NYSE: MRK | 228 | 107 | Enlicitide, Sacituzumab tirumotecan |
| NewAmsterdam Pharma Naarden, the Netherlands | Nasdaq: NAMS | 6 | 3 | Obicetrapib |
| Novartis Basel, Switzerland | NYSE: NVS | 362 | 89 | Pelacarsen |
| Novo Nordisk Bagsværd, Denmark | NYSE: NVO | 146 | 50 | CagriSema |
| Silence Therapeutics London, United Kingdom | Nasdaq: SLN | 1 | 0 | Zerlasiran |
Active means recruiting, not yet recruiting, active (not recruiting), or enrolling by invitation on ClinicalTrials.gov. Phase 3 counts include combined Phase 2/3 trials. Counts reflect trials where the company is the registered lead sponsor.